Brain Manganese Deposition in High Risk Neonates
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00392977|
Recruitment Status : Completed
First Posted : October 26, 2006
Last Update Posted : December 19, 2013
|Condition or disease||Intervention/treatment|
|Necrotizing Enterocolitis Digestive System Abnormalities Cholestasis||Dietary Supplement: remove Mn from PN if evidence of increased brain Mn on MRI|
Manganese (Mn) is an essential metal needed for normal growth and development. Excessive environmental or dietary exposure results in Mn deposition in Mn-sensitive brain regions causing adverse psychological and neurological effects. Sick infants requiring parenteral nutrition (PN) may be at increased risk of Mn neurotoxicity because neonatal PN solutions contain high concentrations of Mn, PN bypasses the normal intestinal absorptive control and biliary excretory mechanisms for Mn, and infants are at a critical stage of brain development. Furthermore, iron (Fe) deficiency, a common problem among sick neonates, increases Mn brain uptake because Mn and Fe compete for the same carrier transport systems in the central nervous system. This proposal will investigate brain deposition of Mn, a paramagnetic element, by magnetic resonance (MR) imaging in 40 neonates receiving Mn-supplemented PN and 10 control infants.
Two specific aims will test the following hypotheses:
Shortening of MR T1 and T2 relaxation times (a marker for Mn) in Mn-sensitive brain regions in neonates receiving PN will correlate directly with
- dietary Mn intake,
- days on PN,
- blood Mn levels (measured by Inductively Coupled Plasma-Mass Spectrometry)
- hepatic dysfunction/cholestasis (assessed by conjugated bilirubin levels).
shortening of T1 and T2 relaxation times will correlate inversely with
- gestational age
- Fe status (assessed by serum Fe, ferritin, transferrin, soluble transferrin receptor and hemoglobin).
The potential for increased brain Mn accumulation in infants and the potential health risks associated with elevated brain Mn burden represent crucial, unexplored issues of exposure and susceptibility. The impact of dietary Mn, and especially parenterally delivered dietary Mn, gestational age, Fe status, and hepatic dysfunction on the ability of the neonatal brain to regulate Mn deposition has not been scientifically addressed. The proposed clinical investigation has enormous health significance and may shed light on the development and progression of neurological dysfunction in infants and children on prolonged parenteral nutrition.
|Study Type :||Observational|
|Actual Enrollment :||43 participants|
|Official Title:||Brain Manganese Deposition in High Risk Neonates|
|Study Start Date :||August 2006|
|Actual Primary Completion Date :||December 2010|
|Actual Study Completion Date :||December 2010|
- Dietary Supplement: remove Mn from PN if evidence of increased brain Mn on MRI
trace element cocktail will be withheld and zinc, copper and chromium added to PN individually.
- Correlation between changes in MR signals and dietary Mn intake, number of days on PN and blood Mn levels [ Time Frame: at hospital discharge and 6 months of age ]
- Comparison of pallidal-white matter T1 ratios and absolute T1 and T2 values in control infants and neonates receiving Mn-supplemented PN. [ Time Frame: at hospital discharge and at 6 months of age ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00392977
|United States, Tennessee|
|Vanderbilt Children's Hospital|
|Nashville, Tennessee, United States, 37232-9544|
|Principal Investigator:||Judy L Aschner, MD||Vanderbilt University Medical Center|